Last reviewed · How we verify
AT13387 and Imatinib
AT13387 is a potent and selective inhibitor of the B-Raf V600E kinase, while Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-Kit, and PDGFR.
AT13387 is a potent and selective inhibitor of the B-Raf V600E kinase, while Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-Kit, and PDGFR. Used for Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL), Gastrointestinal stromal tumors (GIST).
At a glance
| Generic name | AT13387 and Imatinib |
|---|---|
| Also known as | Gleevec |
| Sponsor | Astex Pharmaceuticals, Inc. |
| Drug class | tyrosine kinase inhibitor |
| Target | B-Raf V600E kinase, BCR-ABL, c-Kit, PDGFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
AT13387 works by selectively binding to the B-Raf V600E kinase, thereby inhibiting its activity and potentially leading to cancer cell death. Imatinib, on the other hand, targets multiple tyrosine kinases, including BCR-ABL, c-Kit, and PDGFR, which are involved in the proliferation and survival of cancer cells.
Approved indications
- Chronic myeloid leukemia (CML), Acute lymphoblastic leukemia (ALL)
- Gastrointestinal stromal tumors (GIST)
Common side effects
- Myelosuppression
- Nausea
- Diarrhea
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AT13387 and Imatinib CI brief — competitive landscape report
- AT13387 and Imatinib updates RSS · CI watch RSS
- Astex Pharmaceuticals, Inc. portfolio CI